Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection
Purpose: To determine the role of intravitreal injection (IVI) of brolucizumab for extra-large pigment epithelial detachment (PED) secondary to macular neovascularization (MNV). Observations: A prospective, non-randomized, uncontrolled case series of three eyes of three patients with extra-large PED...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993623000373 |
| _version_ | 1797823683138420736 |
|---|---|
| author | Somnath Chakraborty Jay Umed Sheth |
| author_facet | Somnath Chakraborty Jay Umed Sheth |
| author_sort | Somnath Chakraborty |
| collection | DOAJ |
| description | Purpose: To determine the role of intravitreal injection (IVI) of brolucizumab for extra-large pigment epithelial detachment (PED) secondary to macular neovascularization (MNV). Observations: A prospective, non-randomized, uncontrolled case series of three eyes of three patients with extra-large PED (maximum height >350 μm) due to untreated MNV was undertaken at a single center. All three eyes showed significant improvement in the PED height by week 4, with complete resolution by week 8 in two of the three. The third patient who received the second dose is scheduled for a follow-up. Simultaneous notable visual improvement was also observed in all of the eyes. Furthermore, there were no ocular or systemic safety concerns in any of the cases. Conclusions and Importance: Our real-world case series indicates that intravitreal brolucizumab is efficacious and safe for the management of extra-large PEDs in treatment-naïve MNV eyes. To better understand brolucizumab's mechanism of action, particularly at the sub-RPE and choroidal levels, and the underlying functional principle for the PED response, more study of the drug's pharmacotherapeutics is warranted. |
| first_indexed | 2024-03-13T10:27:36Z |
| format | Article |
| id | doaj.art-1e065fa8bebd4dc99dbc3a9d9eb947e4 |
| institution | Directory Open Access Journal |
| issn | 2451-9936 |
| language | English |
| last_indexed | 2024-03-13T10:27:36Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj.art-1e065fa8bebd4dc99dbc3a9d9eb947e42023-05-19T04:46:11ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362023-06-0130101829Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injectionSomnath Chakraborty0Jay Umed Sheth1Department of Vitreoretinal Services, Retina Institute of Bengal, Siliguri, India; Corresponding author. Retina Institute Of Bengal, 3rd Floor, Uttarapan Market Complex Siliguri, 734003, West Bengal, India.Department of Vitreoretinal Services, Shantilal Shangvi Eye Institute, Mumbai, IndiaPurpose: To determine the role of intravitreal injection (IVI) of brolucizumab for extra-large pigment epithelial detachment (PED) secondary to macular neovascularization (MNV). Observations: A prospective, non-randomized, uncontrolled case series of three eyes of three patients with extra-large PED (maximum height >350 μm) due to untreated MNV was undertaken at a single center. All three eyes showed significant improvement in the PED height by week 4, with complete resolution by week 8 in two of the three. The third patient who received the second dose is scheduled for a follow-up. Simultaneous notable visual improvement was also observed in all of the eyes. Furthermore, there were no ocular or systemic safety concerns in any of the cases. Conclusions and Importance: Our real-world case series indicates that intravitreal brolucizumab is efficacious and safe for the management of extra-large PEDs in treatment-naïve MNV eyes. To better understand brolucizumab's mechanism of action, particularly at the sub-RPE and choroidal levels, and the underlying functional principle for the PED response, more study of the drug's pharmacotherapeutics is warranted.http://www.sciencedirect.com/science/article/pii/S2451993623000373BrolucizumabMacular neovascularizationPigment epithelial detachmentAnti-vascular endothelial growth factor |
| spellingShingle | Somnath Chakraborty Jay Umed Sheth Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection American Journal of Ophthalmology Case Reports Brolucizumab Macular neovascularization Pigment epithelial detachment Anti-vascular endothelial growth factor |
| title | Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection |
| title_full | Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection |
| title_fullStr | Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection |
| title_full_unstemmed | Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection |
| title_short | Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection |
| title_sort | response of extra large pigment epithelial detachment to intravitreal brolucizumab injection |
| topic | Brolucizumab Macular neovascularization Pigment epithelial detachment Anti-vascular endothelial growth factor |
| url | http://www.sciencedirect.com/science/article/pii/S2451993623000373 |
| work_keys_str_mv | AT somnathchakraborty responseofextralargepigmentepithelialdetachmenttointravitrealbrolucizumabinjection AT jayumedsheth responseofextralargepigmentepithelialdetachmenttointravitrealbrolucizumabinjection |